Related Experiment Video
Updated: Oct 9, 2025

Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
How Reproducible Is the Data from Sysmex DI-60 in Leukopenic Samples?
Sumi Yoon1, Mina Hur2, Gun Hyuk Lee2
1Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul 06973, Korea.
Performance of the Sysmex DI-60 digital morphology analyzer was evaluated on white blood cell (WBC) differentials in leukopenic samples. The system
Area of Science:
- Hematology
- Clinical Pathology
- Medical Laboratory Science
Background:
- Digital morphology (DM) analyzers are integral to modern clinical practice.
- Evaluating DM analyzer performance on challenging samples, like leukopenic ones, is crucial.
- Previous studies have not focused specifically on the Sysmex DI-60's performance in leukopenia.
Purpose of the Study:
- To assess the analytical performance and precision of the Sysmex DI-60 system for white blood cell (WBC) differentials in leukopenic peripheral blood samples.
- To determine how WBC count affects the accuracy of DM analysis in leukopenic conditions.
Main Methods:
- Analysis of 40 peripheral blood smears categorized into normal, mild, moderate, and severe leukopenia groups (n=10 each).
- Evaluation of WBC preclassification precision using %coefficients of variation (%CVs).
- Comparison of Sysmex DI-60 differential counts against manual counts to determine mean differences and assess specificity/efficiency.
Main Results:
- Precision (%CVs) varied by sample and cell class, increasing with fewer cells per slide.
- High overall specificity (95.9-99.9%) and efficiency (90.0-99.4%) were observed for most cell classes, excluding plasma cells.
- Mean differences between DI-60 and manual counts increased significantly with the severity of leukopenia, reaching 47.74 in severe cases.
Conclusions:
- The Sysmex DI-60's performance in WBC differentials is significantly influenced by white blood cell count.
- DM analyzers require separate performance evaluations for leukopenic samples, even if overall performance appears acceptable.
- Findings highlight the need for careful validation of DM systems across diverse patient populations, particularly those with low WBC counts.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012